Cyclerion Therapeutics (Cyclerion Therapeutics) Short Percentage of Float

View and export this data going back to 2019. Start your Free Trial

What is Cyclerion Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cyclerion Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Cyclerion Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclerion Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclerion Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cyclerion Therapeutics's Short Percentage of Float falls into.

Cyclerion Therapeutics (Cyclerion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclerion Therapeutics Inc (NAS:CYCN) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

N/A

Address

245 First Street, 18th Floor, Cambridge, MA, USA, 02142

Website

https://www.cyclerion.com

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Executives

Terrance Mcguire	director	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Steven Hyman	director	C/O VOYAGER THERAPEUTICS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Andreas Busch	officer: Chief Scientific Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
George H Conrades	director	500 TECHNOLOGY SQUARE, FIFTH FLOOR, CAMBRIDGE MA 02139
Stephanie Lovell	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Ole Isacson	director	CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kevin Churchwell	director	C/O CYCLERION THERAPEUTICS, CAMBRIDGE MA 02142
Michael Mendelsohn	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Peter M Hecht	director, officer: Chief Executive Officer	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Slate Path Capital Lp	10 percent owner	717 5TH AVENUE, 16TH FL., NEW YORK NY 10022
Errol B Desouza	director	215 COLLEGE ROAD, PARAMUS NJ 07652
Anjeza Gjino	officer: Chief Financial Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Christopher I Wright	officer: Chief Medical Officer	C/O CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Cheryl Gault	officer: Chief Operating Officer	CYCLERION THERAPEUTICS, INC., 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE MA 02142
Mark G Currie	officer: President and CSO	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142